Corporate Profile
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.
As of November 2, 2026, Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. have successfully completed their merger of equals transaction, creating a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, a differentiated pipeline, financial flexibility and the capacity to pursue growth opportunities. The combined company will now operate as Supernus, Inc. and will continue trading on the Nasdaq Global Select Market. The combined company shares will begin trading under the ticker symbol "SUPN" on November 3, 2026.
Supernus Pharmaceuticals, Inc. will now be a wholly owned subsidiary of Supernus, Inc., formerly known as Indivior Pharmaceuticals, Inc.
Minimum 15 minutes delayed. Source: LSEG